GnRH Agonists vs Antagonists: The Flare, and Two Ways to Switch Off the Sex-Hormone Axis

Gonadotropin-releasing hormone (GnRH, also called LHRH) is a small peptide made by the hypothalamus that sits at the top of the reproductive hormone axis. It controls the pituitary's release of two gonadotropins — LH and FSH — which in turn drive the ovaries and testes to make estrogen and testosterone. A whole family of peptide drugs targets the pituitary's GnRH receptor to switch this axis off, and they come in two opposite flavors: agonists and antagonists. Both end up suppressing sex hormones, but the way they get there is strikingly different — and the difference has real clinical consequences.

The key to everything: GnRH works in pulses

The single most important fact about this system is that native GnRH is released in pulses, roughly every 60–90 minutes. That pulsatility is essential. The pituitary is tuned to respond to intermittent signals; steady, continuous stimulation does the opposite of what you might expect — it eventually shuts the pituitary down. This quirk is what makes GnRH agonists work.

GnRH agonists: stimulate, then suppress (the "flare")

A GnRH agonist — leuprolide, goserelin, nafarelin, histrelin, triptorelin — is a modified, super-potent version of GnRH that resists breakdown. Given as a depot, it provides continuous, non-pulsatile receptor stimulation. Two phases follow:

1. The flare (first 1–2 weeks). At first the agonist simply does what GnRH does — it stimulates. LH, FSH, and sex hormones rise. In a man with advanced prostate cancer, this transient testosterone surge can briefly worsen symptoms (bone pain, urinary obstruction), which is dangerous in specific situations.
2. Downregulation and suppression. With continuous exposure, the pituitary GnRH receptors internalize and desensitize. LH and FSH fall, and sex hormones drop to castrate/postmenopausal levels within 2–4 weeks — a reversible medical castration.

Because of the flare, agonists in prostate cancer are usually started with an anti-androgen (like bicalutamide) for the first few weeks to blunt the surge.

GnRH antagonists: block immediately, no flare

A GnRH antagonist — degarelix, the historical abarelix, and the IVF drug cetrorelix — does the opposite. It competitively blocks the GnRH receptor from the start. There is no stimulatory phase, so LH, FSH, and testosterone fall immediately, reaching castrate levels within days. No flare means no anti-androgen cover is needed at the start — an advantage when a testosterone surge would be dangerous.

The oral non-peptide antagonist relugolix extends this concept in a daily pill.

Side-by-side

| Feature | GnRH agonist | GnRH antagonist |

| --- | --- | --- |

| Initial effect | Stimulates (flare) | Blocks (no flare) |

| Time to suppression | 2–4 weeks | Days |

| Anti-androgen needed at start? | Usually, in prostate cancer | No |

| Typical dosing | Depot 1–6 months (or yearly implant) | Monthly depot; some daily |

| Examples | Leuprolide, goserelin, nafarelin, histrelin, triptorelin | Degarelix, abarelix (historical), cetrorelix |

Why both are still used

Antagonists avoid the flare and act fast — attractive when speed matters. But agonists have decades of data and unbeatable convenience: a single histrelin implant lasts a full year, and depot leuprolide or goserelin cover 1–6 months. The choice depends on the clinical situation: an antagonist for rapid, flare-free suppression; an agonist for long-term convenience.

The same targets, opposite jobs

The elegance of this system is that the same receptor can be exploited in opposite ways. In IVF, cetrorelix (an antagonist) blocks a premature LH surge — but a short burst of a GnRH agonist is sometimes used as the ovulation "trigger," using its brief flare on purpose. Understanding the flare is the key that unlocks why these closely related peptides behave so differently. See also our overviews of the hypothalamic-pituitary-adrenal axis and oxytocin in childbirth.

> This article is educational and not medical advice. GnRH-based therapies are prescription treatments used under specialist supervision.